Atractylenolide III attenuates Bleomycin-induced experimental pulmonary fibrosis and oxidative stress in rat model via Nrf2/NQO1/HO-1 pathway activation.

This study aimedto investigate whether AtrIII alleviated BLM-induced PF and oxidative stress in rats through the nuclear factor erythroid-2-related factor 2/NQO1,NAD(P)H:quinineoxidoreductase 1/Heme oxygenase-1 (Nrf2/NQO1/HO-1) pathway.Medium and high doseAtrIII(1.2, 2.4mg/kg)improved the lung injury and lung function in the BLM-induced Sprague-Dawley(SD) rats. AtrIII reduced the apoptosis rate and down-regulated the expression of Caspase-3 and Caspase-9.AtrIII(1.2, 2.4mg/kg)alleviated pulmonary fibrosis damageand down-regulated transforming growth factor-β (TGF-β) and α-smooth muscle actin(α-SMA)expression. AtrIIIalsodown-regulated the levels ofinterleukin 6 (IL-6), inductiblenitric oxide synthase(iNOS) and tumor necrosis factor-α(TNF-α), whileup-regulatedthe level of IL-10 in peripheral blood serum.Moreover,AtrIII(1.2, 2.4mg/kg)increasedthe activity of superoxide dismutase(SOD) and glutathione(GSH), while decreased the malondialdehyde(MDA)contentand lactate dehydrogenase(LDH)activity.AtrIII(1.2, 2.4mg/kg)increased the levels of Nrf2, NQO1 and HO-1.In addition, AtrIII reversed the effects of Nrf2 interference on pulmonary fibrosis damage, decreased SOD and GSH activity, and increased MDA content. Taken together, AtrIIIcould attenuate the pulmonary fibrosis and reliev oxidative stress through the Nrf2/NQO1/HO-1 pathway. PMID: 32762376 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research